Target for Sensitizing Tumor Cells to Radiation and Chemotherapy

Technology #2016-386

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Zhenkun Lou Ph.D.
Bo Qin Ph.D.
Managed By
Panya Taysavang
Patent Protection
US Patent Pending
US Patent Pending

Mayo Clinic has discovered the UFM1 signaling pathway as a biomarker/therapeutic target in cancer. UFM1 is an Ub-like molecule needed for ATM activation and DNA damage response. Inhibiting the pathway could sensitize cancer cells to radiation and chemotherapy.